Behold.ai receives approval for red dot® imaging recognition algorithm.
London-based Behold.ai received 510(k) clearance from the U.S. Food & Drug Administration this week for its automatic diagnosis tool for pneumothorax.
Referring to the tool as an “instant triage,” the company said its red dot® algorithm alerts radiologists as soon as it captures a pneumothorax on a X-ray image.
According to a company statement, the tool not only saves reading time, but it can also help reduce the cost of diagnosis when used in conjunction with other products.
“FDA clearance is not just about safety, but also about efficacy,” said Behold.ai Chief Executive Officer Simon Rasalingham, in a press statement. “We believe our technology can make a big difference to patient safety, the delivery of care and cost-savings to the system.”
Based on company information, customers will be charged on a per exam basis, and red dot® will be commercially available in the United States later this year.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.